Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 8, 2013, Pages

  Yamada, Yoshihisa ^a   Kobayashi, Hiroyuki ^a   Iwasa, Masamitsu ^a   Sumi, Shohei ^a   Ushikoshi, Hiroaki ^a   Aoyama, Takuma ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Takako ^b   Fujiwara, Hisayoshi ^c   Kiso, Makoto ^d   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

^c HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

Akt; Angiogenesis; Erythropoietin; Infarct size; Liposome

Indexed keywords

CD31 ANTIGEN; ERYTHROPOIETIN RECEPTOR; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; SIALYL LEWIS X ANTIGEN; SODIUM CHLORIDE; STAT3 PROTEIN; VASCULOTROPIN; 5-ACETYLNEURAMINYL-(2-3)-GALACTOSYL-(1-4)-(FUCOPYRANOSYL-(1-3))-N-ACETYLGLUCOSAMINE; 5 ACETYLNEURAMINYL (2 3) GALACTOSYL (1 4) (FUCOPYRANOSYL (1 3)) N ACETYLGLUCOSAMINE; ANTIANEMIC AGENT; ERYTHROPOIETIN; INTERSTITIAL COLLAGENASE; OLIGOSACCHARIDE; PERK KINASE; PROTEIN KINASE R; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; MALE; MICROVASCULATURE; MOLECULAR MECHANICS; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; DRUG EFFECT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; EIF-2 KINASE; ERYTHROPOIETIN; HEMATINICS; LIPOSOMES; MALE; MATRIX METALLOPROTEINASE 1; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOSACCHARIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

MLCS; MLOWN;

EID: 84878438055     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00707.2012     Document Type: Article

References (44)

1. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999.
2. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and bepoetin. N Engl J Med 339: 584-590, 1998.
3. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leucocytes adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243: 1160-1165, 1989.
4. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806, 2003.
5. Flynn DM, Buda AJ, Jeffords PR, Lefer DJ. A sialyl LewisX-containing carbohydrate reduces infarct size: role of selectins in myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 271: H2086-H2096, 1996.
6. Gabison A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: view of animal and human studies. Clin Pharmacokinet 42: 419-436, 2003.
7. Gabizon A, Papahadjopoulos D. Liposome formation with prolonged circulation time in blood and enhanced uptake by tumours. Proc Natl Acad Sci USA 85: 6949-6953, 1988.
8. Hale SL, Setti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 64: 211-215, 2005.
9. Hattori R, Hernandez TE, Zhu L, Maulik N, Kaneda Y, Das DK. An essential role of the antioxidant gene Bcl-2 in myocardial adaptation to ischemia: an insight with antisense Bcl-2 therapy. Antioxid Redox Signal 3: 403-413, 2001.
10. Hausenly DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976, 2005.
11. Heeschen C, Aicher A, Lehmann R, Fichtlischer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346, 2003.
12. Hirai M, Minematsu H, Kondo N, Oie K, Igarashi K, Yamazaki N. Accumulation of liposome with sialyl Lewis X to inflammation and tumor region: Application to in vivo bio-imaging. Biochem Biophys Res Commun 353: 553-558, 2007.
13. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, Fu XY. Cardiomyocyterestricted knockout of Stat3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100: 12929-12934, 2003.
14. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104: 2822-2829, 2005.
15. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y, Ushikoshi H, Nishigaki K, Takemura G, Fujiwara T, Tabata Y, Fujiwara H. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 79: 611-620, 2008.
16. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, Nielson TT. Lack of acute cardioprotective administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 25: 305-310, 2005.
17. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, Minatoguchi S, Fujiwara T, Fujiwara H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113: 535-543, 2006.
18. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71: 684-694, 2006.
19. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1128: 44-49, 1992.
20. Minatoguchi S, Takemura G, Chen XH, Wang N, Uno Y, Koda M, Arai M, Misao Y, Lu C, Suzuki K, Goto K, Komada A, Takahashi T, Kosai K, Fujiwara T, Fujiwara H. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarct granulocyte colony-stimulating factor treatment. Circulation 109: 2572-2580, 2004.
21. Minematsu H, Otani T, Oohashi T, Hirai M, Oie K, Igarashi K, Ohtsuka A. Development of an active targeting liposome encapsulated with high-density colloidal gold for transmission electron microscopy. J Electron Microsc (Tokyo) 60: 95-99, 2011.
22. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19: 243-250, 2005.
23. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 100: 662-669, 2007.
24. Olea FD, Vera Janavel G, De Lorenzi A, Cuniberti L, Yannarelli G, Cabeza Meckert P, Cearras M, Laguens R, Crottogini A. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 47: 736-741, 2006.
25. Palani S, Sarkar CA. Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophys J 95: 1575-1589, 2008.
26. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumour therapeutic efficacy. Proc Natl Acad Sci USA 24: 11460-11464, 1991.
27. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662, 2004.
28. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007, 2003.
29. Reemers EE, Cleutjens JP, Smith JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89: 201-210, 2002.
30. Spinale FG. Matrix metalloproteinases: regulation and dysregulation on the failing heart. Circ Res 90: 520-530, 2002.
31. Takeshita S, Zheng LP, Brogi E, Keamey M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 9: 662-670, 1994.
32. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Kim S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102: 246-252, 2000.
33. Tojo SJ, Yokota S, Koike H, Schulz J, Hamazume Y, Misugi E, Yamada K, Hayashi M, Paulson JC, Morooka S. Reduction of rat myocardial ischemia and reperfusion injury by siaryl Lewis x oligosaccharide and anti-rat P-selectin antibodies. Glycobiology 6: 463-469, 1996.
34. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232, 2004.
35. Unezaki S, Maruyama K, Ishida O, Takahashi N, Iwatsuru M. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long circulating liposomes. J Drug Target 1: 287-292, 1993.
36. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 79: 181-213, 1999.
37. Vyas SP, Singh A, Sihorkar V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carrier Syst 18: 1-76, 2001.
38. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033, 2004.
39. Xuan YT, GuoY, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98: 9050-9055, 2001.
40. Yamazaki N. Active targeting DDS. Farumashia 42: 125-129, 2006.
41. Yamazaki N. Analysis of the carbohydrate-binding specificity of lectinconjugated lipid vesicles which interact with polysaccharide fragments. J Membr Sci 41: 249-267, 1989.
42. Yamazaki N, Kodama M, Gabius HJ. Neoglycoprotein-liposome and lectin-liposome conjugates as tools for carbohydrate recognition research. Methods Enzymol 242: 56-65, 1994.
43. Yamazaki N, Kojima S, Yokoyama H. Biomedical nanotechnology for active drug delivery systems by applying sugar-chain molecular functions. Curr Appl Phys 5: 112-117, 2005.
44. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H578-H588, 2003.